Background
PJIs
Edited by: Marie Hallin, Université libre de Bruxelles, BelgiumReviewed by: Youliang Ren, University of Rochester Medical Center, United StatesChaitanya Tellapragada, Karolinska Institutet (KI), Sweden†These authors have contributed equally to this workMetagenomic next-generation sequencing (mNGS) is a culture-independent massively parallel DNA sequencing technology and it has been widely used for rapid etiological diagnosis with significantly high positivity rate. Currently, clinical studies on evaluating the influence of previous antimicrobial therapy on positivity rate of mNGS in PJIs are rarely reported. The present study aimed to investigate whether the positivity rate of mNGS is susceptible to previous antimicrobial therapy.